SEK0.419 0.0 6.1%
Last Trade - 12:34pm
Market Cap | £11.4m |
Enterprise Value | £6.61m |
Revenue | £n/a |
Position in Universe | 1538th / 1850 |
Jan 14 (Reuters) - Cereno Scientific AB CRNOSb.TE : * CERENO SCIENTIFIC SIGNS CRO FOR PHASE II STUDY WITH DRUG CANDIDATE CS1 IN RARE DISEASE PAH * SIGNED A LETTER OF INTENT WITH THE GLOBAL CONTRACT RESEARCH ORGANIZATION (CRO) WORLDWIDE CLINICAL TRIALS * CLINICAL TRIAL APPLICATION PROCESS FOR THE STUDY HAS BEEN INITIATED AND THE STUDY START IS EXPECTED TO BE INITIATED IN MID-2021 Source text for Eikon: ID: Further company coverage: CRNOSb.TE (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))